Upneeq
FDA-approved eye drops for non-surgical eyelid ptosis correction
About This Treatment
Upneeq (oxymetazoline HCl 0.1%) by RVL Pharmaceuticals is the world's first FDA-approved prescription eye drop for acquired ptosis. As an alpha-2 adrenergic agonist, it contracts the Müller's muscle to lift the upper eyelid by approximately 1mm.
Non-surgical "eye-opening" effect for age-related ptosis and Botox-induced drooping. Once-daily application.
Mechanism of Action
Oxymetazoline 0.1% binds alpha-2 adrenergic receptors on Müller's muscle (superior tarsal muscle), inducing smooth muscle contraction to lift the upper eyelid by ~1mm. Unlike Botox, this "promotes contraction" rather than causing paralysis. Effect onset within 15 minutes, lasting 6-8 hours.
Indications
Expected Results
Average 1mm upper eyelid lift from first use. Safety and efficacy confirmed in clinical trials. Sustained with daily use. Also effective for Botox-induced ptosis.
Clinical Evidence
Risks & Side Effects
Mild ocular irritation (immediately after application). Potential rebound ptosis with abrupt discontinuation. Minimal effect on IOP but caution in glaucoma patients. Avoid concurrent decongestant use. Prescription required.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition